Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial
Authors' conclusion
Although the overall number of anti-VEGF injections in the target eye showed no significant difference, some patients responded favourably to SGLT2i and required fewer injections. The reduction in fellow eye injections suggests SGLT2i's efficacy in treating early-stage DMO.
Study context
- Population
- Patients with T2D and diabetic macular oedema (DMO) eligible for anti-VEGF therapy; mostly with DR, half previously treated with anti-VEGF therapy
- Participants
- 60 patients
- Comparison
- Luseogliflozin vs glimepiride, with ranibizumab
- Primary endpoint
- Number of ranibizumab doses (target eye)
- Follow-up
- Up to week 48
Methodological detailsmulticentre, open-label
- Multicentre
- Open-label
Primary result
As reported in the abstract
Injection frequency, target eye
P = 0.36
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Re-administration after the fourth injectionDecreased significantly in SGLT2i | 0.45 (0.22–0.92) | P = 0.030 | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | SGLT2i | SU | P value |
|---|---|---|---|
| Fellow eye injectionsFewer with SGLT2i | 1.3 ± 0.6 | 3.4 ± 0.8 | P = 0.016 |
Fellow eye injections
- Fellow eyes in SGLT2i showed significant central retinal thickness (CRT) reduction vs SU
HbA1c, CRT and best-corrected visual acuity
- Equivalent improvements in SGLT2i and SU
Original publication
Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial. Diabetes Obes Metab. Published 11 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →